Suk Jin Ha

Dr. Suk Jin Ha

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2014 in Journal of Biotechnology
Verified
Journal Article
Closed access
YCYuna Cheon
Yuna Cheon
Jun-Seob KimJun-Seob Kim
Jun-Seob Kim
JPJun-Bum Park
Jun-Bum Park
PHPaul Heo
Paul Heo
JLJae Hyung Lim
Jae Hyung Lim
Dae-Hyuk KweonDae-Hyuk Kweon
Dae-Hyuk Kweon

20 October 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
YKYeongbeom Kim
Yeongbeom Kim
JKJaewoo Kwak
Jaewoo Kwak
MLMinyeong Lim
Minyeong Lim
SLSu Yeon Lim
Su Yeon Lim
SCSehyun Chae
Sehyun Chae
Kwang Suk LimKwang Suk Lim
Kwang Suk Lim
Biodegradable polymers such as Polycaprolactone (PCL), Polylactic acid (PLA), and Poly(lactic-co-glycolic acid) (PLGA) are attracting attention as key platforms for anticancer drug delivery systems due to their excellent biocompatibility and controllable degradation rates. These polymers can overcome limitations of existing chemotherapeutics, such as low bioavailability, systemic toxicity, and nonspecific cell damage, and contribute to the development of precision medicine approaches and long-acting therapeutics. This paper discusses the chemical and physicochemical properties of these three polymers, their synthetic strategies, and the controlled drug release technology through surface functionalization and stimuli-responsive design. Furthermore, we highlight their potential for use in various formulations, including micelles, nanoparticles, hydrogels, and microspheres, enabling enhanced drug solubility, sustained release, and tumor targeting. Preclinical and clinical applications demonstrate that these polymer-based DDSs represent a promising approach for implementing next-generation precision anticancer treatment strategies, with further potential for clinical translation and widespread adoption.

16 September 2014 in Nutrients
Verified
Journal Article
Open access
PDF file
JPJun Myoung Park
Jun Myoung Park
JLJong Seok Lee
Jong Seok Lee
KLKi Rim Lee
Ki Rim Lee
SHSuk Jin Ha
Suk Jin Ha
EHEock Kee Hong
Eock Kee Hong
Oxidative stress induced by reactive oxygen species (ROS) is the major cause of degenerative disorders including aging and disease. In this study, we investigated whether Cordyceps militaris extract (CME) has in vitro protective effects on hydrogen peroxide-induced oxidative stress in human dermal fibroblasts (HDFs). Our results showed that the 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical scavenging activity of CME was increased in a dose-dependent manner. We found that hydrogen peroxide treatment in HDFs increased ROS generation and cell death as compared with the control. However, CME improved the survival of HDFs against hydrogen peroxide-induced oxidative stress via inhibition of intracellular ROS production. CME treatment inhibited hydrogen peroxide-induced apoptotic cell death and apoptotic nuclear condensation in HDFs. In addition, CME prevented hydrogen peroxide-induced SA-β-gal-positive cells suggesting CME could inhibit oxidative stress-induced premature senescence. Therefore, these results suggest that CME might have protective effects against oxidative stress-induced premature senescence via scavenging ROS.

30 April 2017 in Food Science and Biotechnology
Verified
Journal Article
Closed access
PDF file
JPJae-Bum Park
Jae-Bum Park
SLSeung-Hee Lim
Seung-Hee Lim
HSHyun-Su Sim
Hyun-Su Sim
JPJoong-Hee Park
Joong-Hee Park
HKHun-Joo Kwon
Hun-Joo Kwon
SHSuk Jin Ha
Suk Jin Ha

5 June 2015 in Applied Biochemistry and Biotechnology
Verified
Journal Article
Closed access
PDF file
JKJin-Seong Kim
Jin-Seong Kim
JPJae-Bum Park
Jae-Bum Park
SJSeung-Won Jang
Seung-Won Jang
SHSuk Jin Ha
Suk Jin Ha

8 October 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
KYKim Yerim
Kim Yerim
JPJisu Park
Jisu Park
JCJaewon Choi
Jaewon Choi
MKMinse Kim
Minse Kim
GSGyeongsu Seo
Gyeongsu Seo
Hyun-ouk KimHyun-ouk Kim
Hyun-ouk Kim
Lipid nanoparticles are a clinically validated platform for delivering nucleic acids, but performance is constrained by multiscale physiological barriers spanning circulation, vascular interfaces, extracellular matrices, cellular uptake, and intracellular trafficking. This review links composition–structure–function relationships for ionizable lipids, helper phospholipids, cholesterol, and PEG-lipids to systemic fate, endothelial access, endosomal escape, cytoplasmic stability, and nuclear transport. We outline strategies for tissue and cell targeting, including hepatocyte ligands, immune and tumor selectivity, and selective organ targeting through compositional tuning, together with approaches that modulate escape using pH-responsive chemistries or fusion-active peptides and polymers. We further examine immunomodulatory co-formulation, route and schedule effects on biodistribution and immune programming, and manufacturing and stability levers from microfluidic mixing to lyophilization. Across these themes, we weigh trade-offs between stealth and engagement, potency and tolerability, and potency and manufacturability, noting that only a small fraction of endosomes supports productive release and that protein corona variability and repeat dosing can reshape tropism and clearance. Convergence of standardized assays for true cytosolic delivery, biomarker-guided patient selection, and robust process controls will be required to extend LNP therapeutics beyond the liver while sustaining safety, access, and scale.